Information Letter of the European LeukemiaNet

Created by: Ihrig (ELIC) , generated 2006/02/14, last changed: 2016/01/29

The Information Letter is provided once per year before the annual Symposium of the European LeukemiaNet. It is a collaboration of the European Leukemia Information Center (ELIC), the Network Management Center (NMC), and the contributing authors. Topics of this online-publication medium range from basic research to clinical trials and the latest activities of the different work packages.

All ELN members are cordially invited to submit proposals of their field of research for prospective Information Letters to ELIC.


Current issue of the ELN Information Letter

  • Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: Registry results from the PROMYSE project of the ELN
  • TP53 defect: The irrepressible fortress in chronic lymphocytic leukemia?
  • Chronic lymphocytic leukemia: The impact of newly accepted therapies
  • Current status of interferon-based regimens ongoing worldwide for chronic myeloid leukemia patients
  • Prognosis of long-term survival in patients with chronic myeloid leukemia
  • MDS-prognosis according to IPSS and IPSS-R by CD34 FISH of peripheral blood cells
  • MDS-RIGHT: Providing the right care to the right patient with Myelodysplastic Syndrome at the right time
  • EU-Regulation: Timelines and characteristics
  • Experts unite to form a new global acute myeloid leukemia network
  • ASH 2015: Abstract summaries

Privious issues of the ELN Information Letter

Information Letter no. 11

  • Clinical endpoints for drug treatment trials in BCR-ABL1-negative classic MPNs
  • Survival and prognosis in patients with first-line imatinib under particular consideration of death due to CML
  • Incidence of CML in Europe - An estimation from the EUTOS population-based registry
  • Genetic elucidation of oncogene amplification in MDS and AML
  • Pregnancy in patients with chronic myeloid leukemia: ELN CML Pregnancy Registry
  • EUMDS Registry: Ongoing activities and developments
  • DACOTA TRIAL for advanced proliferative CMML by the GFM, FISM and GMDS study groups
  • MDM-portal: A portal of medical documentation forms for leukemia research
  • EU-Regulation: Consequences for academic research
  • ASH 2014: Abstract summaries

Information Letter no. 10

  • WP11 – CYTOGENETICS: Current and future activities in Cytogenetics
  • WP5 – AML: The importance of minimal residual disease (MRD) in AML
  • WP14 - SCT: Role of stem cell transplantation in elderly patients with AML
  • WP8 – MDS: Diagnosis and treatment of primary myelodysplastic syndromes in adults. Recommendations from the European
  • LeukemiaNet
  • WP4 – CML: CML immunology: an update
  • WP6 – ALL: Philadelphia Positive Acute Lymphoblastic Leukemias in the elderly: a European LeukemiaNet perspective
  • WP10 – DIAGNOSTICS: Projects 2013-2014
  • WP8 – MDS: ABT-737 targets NRAS by inhibiting its partner BCL-2
  • EUTOS: Highlights of EUTOS
  • ELN FOUNDATION: News from ELN Foundation
  • ASH 2013: Abstract summaries

Information Letter no. 9

  • WP5 – AML: Towards an integrated, risk adapted application of allogeneic stem cell transplantation for patients with AML in first complete remission
  • WP6 – ALL: Current approaches for antibody therapy in acute lymphoblastic leukemia (ALL)
  • WP11 – Cytogenetics: Quality assurance in leukemia cytogenetics by web-based processing of interlaboratory tests
  • WP4 – CML: European LeukemiaNet recommendations for the management and the treatment of chronic myeloid leukemia
  • WP15 – Supportive care: Recommendations on the management of respiratory viral infections
  • WP8 – MDS: Highlights from the MDS European LeukemiaNet WP 8
  • WP10 – Diagnostics: Highlights from the field of diagnosis
  • WP7 – CLL : European Research Initiative on CLL (ERIC) / ELN WP7
  • WP2 – ELIC: New European regulation on clinical trials on medicinal products for human use
  • EUTOS: Standardized definitions of molecular response in CML
  • ASH 2012: Clinical Results from Oral Presentations Summary of Selected Abstracts

Information Letter no. 8

  • WP8 – MDS: Highlights from the MDS field: European LeukemiaNet
  • WP8 – MDS: TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
  • WP8 – MDS: Flow cytometry in myelodysplastic syndromes. Definitions, Clinical and Diagnostic Applications
  • WP4 – CML: Euro-SKI: Europe stop tyrosine kinase trial – the rational
  • WP5 – AML: The Role of Age versus Treatment Intensity in AML
  • WP9 – MPN: A novel murine model of MPN, generated by NF-E2 overexpression, displays spontaneous transformation to acute leukemia
  • WP6 – ALL: Recommendations of the European Working Group for Adult ALL
  • WP6 – ALL: Clinical Trials Directive – planned amendment by the EU
  • WP7 – CLL: European Research Initiative on CLL (ERIC)
  • ELN Foundation: Two Years of ELN Foundation
  • EUTOS for CML: Latest News about EUTOS
 

Information Letter no. 7

  • WP4 – CML: To stop treatment with Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
  • WP9 – CMPD: SNP-Array Based Analysis in Myeloproliferative Neoplasms
  • WP11 – Cytogenetics: Whole genome sequencing
  • WP4 – CML: The EUTOS for CML Registry
  • WP5 – AML: Prospective comparison of different treatments with a common standard Treatment-Study by the German AML Intergroup
  • WP5 – AML: EBMT/ELN study for elderly patients with AML
  • WP5 – AML: TET2 Mutations in Acute Myeloid Leukemia (AML)
  • WP6 – ALL: Bispecific T-cell engaging (BiTE) Antibody Blinatumomab
  • WP9 – CMPD: Philadelphia-Negative Classical MPN: Critical concepts and Management Recommendations
  • WP10 – Diagnostic Platform: A European consenus report on blood cell identification
  • WP12 – MRD: A step in the right direction towards standardized reporting of minimal residual disease data
  • WP2 – ELIC: EU-directive on good clinical practice: Impact for independent research?
  • WP1 – NMC: ESF-ELN Research Networking Programms
 

Information Letter no. 6

  • WP4 – CML: Update of ELN treatment recommendations for chronic myeloid leukemia
  • EUTOS for CML: A successful collaboration
  • WP5 – AML: Is there a role for immunotherapy in maintaining complete remission in acute myeloid leukemia?
  • WP5 – AML: Developments in APL
  • WP5 – AML: Prospective Assessment of Outcome Determinants in AML: An ELN Pilot Project
  • WP14 – SCT: Main factors predicting outcome after hematopoietic stem cell transplantation
  • WP11 – Cytogenetics : Polymorphisms of DNA repair and detoxification genes in chronic lymphocytic leukemia
  • WP2 – ELIC: ELIC for impact assessment of EU-directive on good clinical practice
  • Network News: ELN Foundation, ALL: Acute lymphoblastic leukemia, Dates/Meetings, Ongoing studies of the European LeukemiaNet in the ELTR, Recommendations and Guidelines
 

Information Letter No.:

Content:

Cover_100x150.jpg

5th Information Letter
 
  September 2008

Download PDF  1,4Mb

  • Project 4 CML: European Registry of chronic myelogenous leukemia patients in failure after imatinib therapy
  • Project 5 AML: ChIP- chip microarrays to study the epigenome in leukemia
  • Project 6 ALL: Important steps towards diagnostic standardization
  • Project 7 CLL: New aspects of the updated guidelines for the diagnosis and treatment of chronic lymphocytic leukemia
  • Project 13 Gene Profiling: Gene Analysis Platform (GAP) for ELN
  • Network News: 1st ELN Workshop on international investigator-initiates-trials, ELTR News, A novel collaboration between academia and industry to improve treatment in CML, Dates & Meetings, Ongoing studies
Information-Letter_04_final.gif

4th Information Letter

October 2007

Download PDF  2Mb

  • Project 4 CML: The CML Group within the European Leukemia Network agreed on a long term Collaboration with Novartis
  • Project 5 AML: The AML Intergroup: A Model of Cross-Trial Networking
  • Project 6 ALL: Progress in Initiation of Paneuropean Trials
  • Project 7 CLL: Finding Solutions for IGHV gene mutational Analysis in CLL
  • Project 11 Cytogenetics: Correlation of whole Genome tiling Resolution Array CGH with Affymetrix Array Expression Analysis in AML/MDS Patients with 11q/MLL Amplification
  • Project 2 ELIC: The German Leukemia and Lymphoma Patients’ Association and the European Cancer Patient Coalition
  • Project 8 MDS: Development of a frailty Index for elderly Patients with MDS and AML by applying a multimodal geriatric Assessment including Quality of life Evaluation
  • Project 6 ALL:Patient Information for ALL in Eight European Languages
  • Project 15 Supportive Care: New Guidelines for Preventing and Treating infectious Diseases in leukemic Patients
InformationLetter_03.jpg

3rd Information Letter

January 2007

Download PDF 1,2Mb

  • Project 4 CML: Recommendations for treatment of CML
  • Projects 10 CLL & 13 Geneprofiling: Joint meeting at MLL, Munich
  • Project 12 MRD: Development of real-time PCR
  • Project 2 ELIC: European Leukemia Trial Registry
  • Project 8 MDS: MDS Registry
  • Project 9 CMPD: Consensus definition of resistance to Hydroxyurea in ET
  • Project 11 Cytogenetics: t(16;21) (AML1-MTD16) with karyotype evolution identified in a de novo AML M1 patient
  • Project 14 SCT:The unmet need for infrastructure in hematopoetic stem cell transplantation (HSCT)
IL2.jpg

2nd Information Letter

June 2006

Download PDF 4,4Mb

  • Project 6 ALL: Acute lymphoblastic leukemia
  • Project 7 CLL: European Research Initiative on Cll (ERIC)
  • Project 8 MDS: Actual state of WP 8 (MDS)
  • Project 11 Cytogenetics: Analysis of AMl/MDS Patient with 11q/Mll Gene Amplification
  • Project 14 Stem Cell Therapy: Stem Cell Transplantation Activity in europe 2004
  • Project 2 ELIC: Clinical Trials Registry
  • Project 2 ELIC: Re-launch of the ELN-Website
IL1.jpg

1st Information Letter

August 2005

Download PDF 1,9Mb

  • Project 1 NMC: News from the Network Management Center Dates, Meetings
  • Project 2 ELIC: Services provided by the European Leukemia Information Center
  • Project 4 CML: Actual state of WP 4 (CML)
  • Project 5 AML: Experiences from a Network of AML Trials using General Up-Front Randomization and a Common Standard Treatment Arm
  • Project 11 Cytogenetics: Consensus protocols for cytogenetic diagnostics in leukemia
  • Project 9 CMPD: Progress report Chronic Myeloproliferative Disorders
  • Project 10 Diagnostic platform: European Immunophenotyping Panels
  • Project 16 New Drugs:ELTRA: European Leukemia Treatment Research Association

Editorial-Board

  • Marie C. Béné
  • Steven O’Brien
  • Alan Burnett
  • Guido Finazzi
  • Christa Fonatsch
  • Eliane Gluckman
  • Nicola Gökbuget (Editor-in-Chief)
  • David Grimwade
  • Torsten Haferlach
  • Jörg Hasford
  • Rüdiger Hehlmann
  • Dieter Hoelzer
  • Per Ljungmann
  • Emili Montserrat
  • Dietger Niederwieser
  • Susanne Saussele
  • Hubert Serve
  • Bengt Simonsson
  • Theo J. M. de Witte

 

Print this Document   Sitemap   Contact  
Online Registration
 
How to join the European LeukemiaNet More ...
EUTOS
EUTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe More ...


 
top